FindTrial
Sign In

Safety and efficacy testing of Ningen Petunia Radiance Cream

A monocentric, open-label single arm prospective clinical study to evaluate the safety and efficacy of Ningen Petunia Radiance Cream on skin radiance, hydration, elasticity and dark spots in healthy adult human females subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044192
Enrollment
30
Registered
2022-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Ningen Petunia Radiance Cream: One FTU (fingertip unit, 0.5 gm) twice daily for 30 days. Control Intervention1: NA: NA

Sponsors

Arbro Pharmaceuticals Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subject must meet all of the following criteriaâ??s in order to be included in the study. 1. Subject in generally good health. 2. Subject between the age group of 18 and 55 years. 3. Subject has not participated in a similar clinical investigation in the past four weeks. 4. Subject willing to abstain from using any product, besides the provided product during the entire study course. 5. Subject willing to visit the site at specified frequencies for periodic evaluations. 6. Subject willing to comply with study specific re requirements. 7. Subject willing to give a written informed consent and come for regular observation.

Exclusion criteria

Exclusion criteria: Patient must have none of the following criteria in order to be included in the study. 1. A known history or present condition of allergic response to any Cosmetic products. 2. Subject with known allergy/ sensitivity to cosmetic products or fragrance and without any skin allergies infections. 3. Subject under any dermatological treatment / prescribed medications. 4. Skin disease (e.g. psoriasis, atopic dermatitis or other cutaneous manifestations on the scalp), which would interfere with the test readings. 5. Any cutaneous conditions on test site (scars, moles, papules etc.) 6. On medications (e.g. steroids or antihistamines), which would compromise the study. 7. Currently or has been undergoing dermatologist facial treatments or procedures within the last 1 month. 8. Subject viewed by the investigator as not being able to complete the study or participating in another study.

Design outcomes

Primary

MeasureTime frame
To evaluate the effects of a cosmetic product for:- Hydration Elasticity Dark spotsTimepoint: Day1, Day7, Day14 and Day 30—

Secondary

MeasureTime frame
Measurement of skin hydration effects by Corneometer Measurement of skin elasticity effects by Cutometer Measurement of skin melanin or erythema effects by Mexameter Timepoint: Day1, Day7, Day14 and Day 30—

Countries

India

Contacts

Public ContactAnshika Rawat

Auriga Research Private Limited

manojkarwa@aurigaresearch.com01244006445

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026